Synthesis and Pharmacological Evaluation of Novel Non-nucleotide Purine Derivatives as P2X7 Antagonists for the Treatment of Neuroinflammation
作者:Francesco Calzaferri、Paloma Narros-Fernández、Ricardo de Pascual、Antonio M.G. de Diego、Annette Nicke、Javier Egea、Antonio G. García、Cristóbal de los Ríos
DOI:10.1021/acs.jmedchem.0c02145
日期:2021.2.25
Several P2X7 antagonists have been developed, though none of them reached clinical trials for this indication. In this work, we designed and synthesized novel blood–brain barrier (BBB)-permeable derivatives as potential P2X7 antagonists. They comprise purine or xanthine cores linked to an aryl group through different short spacers. Compounds were tested in YO-PRO-1 uptake assays and intracellular calcium
ATP 门控 P2X7 嘌呤能受体 (P2X7) 参与许多神经退行性疾病 (NDD) 的发病机制。已经开发了几种 P2X7 拮抗剂,但没有一种达到该适应症的临床试验。在这项工作中,我们设计并合成了新型血脑屏障(BBB)渗透性衍生物作为潜在的 P2X7 拮抗剂。它们包含通过不同的短间隔基与芳基连接的嘌呤或黄嘌呤核心。在表达人 P2X7 的 HEK293 细胞系中的 YO-PRO-1 摄取测定和细胞内钙动力学、非洲爪蟾卵母细胞中的两电极电压钳记录以及小鼠腹膜巨噬细胞中的白细胞介素 1β 释放测定中测试了化合物。通过平行人工膜渗透性测定和 P-糖蛋白 ATP 酶活性评估 BBB 渗透性。二氯芳基嘌呤基乙醇具有一定的 P2X7 阻断作用,为化合物6 (2-(6-氯-9 H-嘌呤-9-基)-1-(2,4-二氯苯基)乙烷-1-酮),命名为 ITH15004,是最有效的,选择性且 BBB 通透性拮抗剂。